Wang, Zhiquan http://orcid.org/0000-0002-8243-7251
Yan, Huihuang http://orcid.org/0000-0003-0756-2922
Boysen, Justin C.
Secreto, Charla R.
Tschumper, Renee C.
Ali, Dania
Guo, Qianqian
Zhong, Jian http://orcid.org/0000-0001-7157-603X
Zhou, Jiaqi
Gan, Haiyun
Yu, Chuanhe
Jelinek, Diane F.
Slager, Susan L. http://orcid.org/0000-0002-5173-4712
Parikh, Sameer A. http://orcid.org/0000-0002-3221-7314
Braggio, Esteban
Kay, Neil E. http://orcid.org/0000-0002-5951-5055
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA015083)
Leukemia Research Foundation
Mayo Clinic Center for Individualized Medicine
Article History
Received: 21 January 2022
Revised: 18 May 2022
Accepted: 7 June 2022
First Online: 1 July 2022
Competing interests
: NEK Advisory Board for Abbvie, AstraZeneca, BeiGene, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology. DSMC (Data Safety Monitoring Committee) for Agios Pharm, AstraZeneca, BMS/Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, Rigel. Research funding from Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals. SAP: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which SAP is a principal investigator. SAP has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Adaptive Health, Adaptive Biotechnologies, and AbbVie (he was not personally compensated for his participation).